CN102711779A - Composition containing black ginseng extracts for preventing or treating liver cancer - Google Patents
Composition containing black ginseng extracts for preventing or treating liver cancer Download PDFInfo
- Publication number
- CN102711779A CN102711779A CN2010800554591A CN201080055459A CN102711779A CN 102711779 A CN102711779 A CN 102711779A CN 2010800554591 A CN2010800554591 A CN 2010800554591A CN 201080055459 A CN201080055459 A CN 201080055459A CN 102711779 A CN102711779 A CN 102711779A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- crow
- radix ginseng
- main body
- steaming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007270 liver cancer Diseases 0.000 title abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 title abstract description 3
- 235000020710 ginseng extract Nutrition 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title description 32
- 235000008434 ginseng Nutrition 0.000 claims abstract description 177
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 176
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 176
- 238000000034 method Methods 0.000 claims abstract description 55
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 22
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 22
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 177
- 238000010025 steaming Methods 0.000 claims description 73
- 238000001035 drying Methods 0.000 claims description 29
- 238000009835 boiling Methods 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 15
- 235000013402 health food Nutrition 0.000 claims description 6
- 235000002791 Panax Nutrition 0.000 claims description 5
- 241000208343 Panax Species 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000010411 cooking Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 241001527087 Panax vietnamensis Species 0.000 claims description 3
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 61
- 239000000843 powder Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229940107131 ginseng root Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- -1 external preparation Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001415930 Corvus monedula Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000180664 Panax wangianus Species 0.000 description 1
- 235000003138 Panax wangianus Nutrition 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000010422 internal standard material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011889 obduction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a method for specifically increasing Rg3 ingredients from among the ginsenoside ingredients of black ginseng. The black ginseng extracts prepared by the method exhibit a high anticancer activity against human liver cancer cells. Further, it has been verified that the method of the present invention has the effect of decreasing the content of benzopyrene which is known to be mainly generated during heating.
Description
Technical field
The present invention relates to a kind of method for preparing crow ginseng, it comprises the green ginseng that surpasses 4 years is separated into Radix Ginseng main body and Radix Ginseng palpus, and they are dried to Radix Ginseng and with steaming and decocting and drying steps repeatedly several times.
More specifically, the present invention relates to a kind of method for preparing the crow ginseng, said crow ginseng has the benzopyrene stability and the Rg of increase
3Composition and effectively the prevention or the treatment hepatocarcinoma.
Background technology
Radix Ginseng is a kind of herbaceos perennial, belongs to the Liao Dong Cortex araliae chinensis family of Dicotyledoneae Umbellales.Radix Ginseng is grown in the forest of remote mountain areas.Radix Ginseng is planted as medicinal plants.Radix Ginseng has humanoid root, so be called Radix Ginseng.The age is depended in the formation of Radix Ginseng, when root growth in the time of 4 to 6 years, gathers in the crops it.The Radix Ginseng of results is called green ginseng when it is ripe, and exsiccant green ginseng is called Radix Ginseng.The green ginseng of steaming and decocting becomes redness, and it is called Radix Ginseng Rubra.Steaming and decocting Radix Ginseng Rubra and drying become black several times, and it is called the crow ginseng.Known to such Radix Ginseng Rubra and the Wu Canshi of boiling and drying, change their medicinal ingredient, thereby, compare with green ginseng, to people's healthy and helpful active component increase.Known Radix Ginseng Rubra is included in the ginsenoside Rb in the saponin with the major physiological composition of crow ginseng
1, Rb
2, Rc, Rd, Re, Rg
1, Rg
2, Rg
3, Ro or the like.
Especially known the ginseng with crow compared ginsenoside-Rg
3Composition increases more crow ginseng.The crow ginseng has developed into a kind of new product recently, thereby it is not recorded as bread and cheese.Yet, because the crow ginseng comprises ginsenoside-Rg
3Composition can be processed into it pouch or concentrate and be classified into the processed food of Radix Ginseng Rubra.Through consumer experience, confirmed that the crow ginseng improves immunity and improves anti-cancer function and sexual function effectively.In addition, the result of study through the experience and the inventor confirms that the crow ginseng is effective to hepatitis, diabetes and liver cirrhosis.
The inventor has has researched and developed a kind of method (seeing Korean Patent no.10-529475) that can increase ginsenoside's composition of crow ginseng.In addition, they have researched and developed a kind of Rg that especially can increase in ginsenoside's composition
3Method.With known increase ginsenoside Rg
3The open no.840003 of the uncensored patent of Korea S compare, the present invention provides a kind of can increase more Rg
3The new method of composition.
The present invention proposes a kind of method for preparing the crow ginseng, and it is below horizontal that this method can be removed benzopyrene to safety criterion, in heating steps, produces benzopyrene during the known preparation crow ginseng.Benzopyrene is the yellow crystal solid, and it belongs to the group of polycyclic aromatic hydrocarbon (PAHs).In the food, when Hydrocarbon, protein, fat etc. decompose under 300～600 ℃ temperature, because imperfect combustion produces known benzopyrene.Recently, reported even in the food of processing, produced benzopyrene being no more than under 100 ℃ the temperature.International cancer research institution (IARC) has carried out benzopyrene toxicity detection for the first time and has carried out detecting for the second time in August, 2006 in 1989, thereby benzopyrene is classified into first group of human carcinogen.The open no.2009-93310 of the uncensored patent of Korea S discloses the preparation of black ginseng and the minimizing of benzopyrene.Designed this method so that through the control baking temperature, benzopyrene does not increase.Yet, designed and removed benzopyrene when method of the present invention increases with convenient drying steps.Therefore, method of the present invention is different with the method for the open no.2009-93310 of the uncensored patent of Korea S.
In addition, the inventor has found that black conopsea extraction of the present invention has shown the optionally good result of antagonism hepatocarcinoma.Anticancer effect about black conopsea extraction; The open no.2006-83301 of the uncensored patent of Korea S discloses the effect of antagonism colorectal cancer; And the open no.2008-106077 of the uncensored patent of Korea S discloses the effect of antagonism Cancerous disease and oxidation diseases associated, but the selectivity effect of the antagonism hepatocarcinoma among these effects and the present invention is irrelevant.
Summary of the invention
Technical problem
The purpose of this invention is to provide the green ginseng of a kind of use more than 4 years and prepare crow ginseng main body and black method of joining root hair, they have the ginsenoside Rg of increase
3And through control boiling temperature and time decreased benzopyrene.
Another object of the present invention provides a kind of method for preparing crow ginseng main body and crow ginseng root hair, and they effectively prevent or treat hepatocarcinoma.
Technical scheme
The present invention relates to a kind ofly prepare the method that crow is joined through steaming and decocting repeatedly and dry green ginseng, this method comprises:
(first process) cleaned Radix Ginseng and it separated into the step of Radix Ginseng main body and Radix Ginseng palpus;
(second process) dry Radix Ginseng main body and Radix Ginseng that cleans must make their moisture be no more than 14% step;
(the 3rd process) distinguished the Radix Ginseng main body and 8～10 hours the step of Radix Ginseng palpus of boiling and drying under 80～90 ℃ temperature;
(the 4th process) distinguished the Radix Ginseng main body and 3～5 hours the step of Radix Ginseng palpus of drying and cooking under 25～50 ℃ temperature;
Steaming and decocting in (five faults in diagnosis and treatment journey) continuous 5～12 repetition the 3rd processes and 25～50 ℃ of exsiccant steps in the 4th process; With
(the 6th process) be dry repetition steaming and decocting and dry crow ginseng main body and the root hair that obtains from the five faults in diagnosis and treatment journey under 25～50 ℃ temperature, makes their moisture finally be no more than 10% step.
The Radix Ginseng that uses in first process can be the Radix Ginseng in 4 to 6 years.
When in first process, separating Radix Ginseng main body and Radix Ginseng palpus, do not peel off their surface.Therefore, should avoid the loss of the saponin of the formation between Radix Ginseng main body and surface.
The moisture of the dry Radix Ginseng in second process preferably suitably is about 5～14%.
Preferably 80～90 ℃ of the boiling temperatures of the 3rd process.When temperature is lower than 80 ℃, the ginsenoside Rg
3Composition does not have large increase and does not well remove benzopyrene.Yet temperature surpasses 90 ℃, Rg
3Composition does not have large increase yet and benzopyrene is not removed to the safety criterion level.
Accomplish the 3rd and the five faults in diagnosis and treatment journey after, other five to ten secondary boiledly add last initial steaming and decocting, total steaming and decocting number of times preferably 6 to 13.When total steaming and decocting number of times less than six the time, the ginsenoside Rg
3Composition does not have large increase and benzopyrene is not removed to the safety criterion level.Along with total steaming and decocting number of times increases, Rg
3Composition increases, but other ginsenoside's composition reduces or disappears.Therefore, should better controlled steaming and decocting number of times and time.
In the preparation of function medicament, can use pulverulent material and solvent (pure water or ethanol) extract according to crow ginseng main body according to the present invention and root hair, function medicament comprises health food with anti-cancer function or tablet, capsule, pill, liquid or the like.
Prepare above-mentioned crow ginseng main body and root hair extract, comprise:
Exsiccant crow ginseng main body or root hair are pressed into the step of fine powder;
With above-mentioned powdery crow ginseng main body or root hair and every 1kg above-mentioned powdery crow ginseng main body or root hair 5～120L temperature is that 70～90 ℃ pure water mixes, then 5～10 hours step of this mixture of stirring under the rotating speed of 50～70rpm;
Precipitate this stirring extract 2～14 hours and precipitate is separated into liquid and solid step; With
Filter the said extracted thing to obtain not having the step of solid filtrating.
Can crow be joined in main body and the pharmaceutical preparation or food of root hair extract with form of powder adding preparation through lyophilization, hot air drying or spray drying etc.
The Radix Ginseng of this paper definition is a herbaceos perennial; Belong to the Panax; And comprise Radix Ginseng (Panaxginseng), Radix Panacis Quinquefolii (Panax quinquefolia), Radix Notoginseng (Panax notoginseng), Panax vietnamensis Ha et Grushv. (Panax vietnamensis), Panax pseudo-ginseng Wall. var. elegantior (Burkill)Hoo & Tseng (Panax elegatior), narrow leaf Rhizoma Panacis Japonici (Panaxwangianus), Rhizoma Panacis bipinnatifidi (Panax bipinratifidus), preferably ginseng or Radix Panacis Quinquefolii.
Extract through to crow ginseng main body and root hair carries out lyophilization, hot air drying or spray drying; Can use to comprise the medical composition that can join main body and root hair as the crow of the medicament of treating cancer according to of the present invention, for example powder, granule, tablet, capsule, suspension, emulsion, syrup or aerocolloidal form are prepared them with oral formulations, external preparation, suppository and sterile injection according to common method.
Comprising carrier, adjuvant and the diluent that can comprise in the compositions of crow ginseng main body and root hair comprises; For example, sucrose, lactose, glucose, sorbitol, mannitol, xylitol, erythritol, maltose alcohol, starch, arabic gum, sodium alginate, gelatin, calcium phosphate, calcium silicates, cellulose, methylcellulose, microcrystalline Cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, nipasol, Pulvis Talci, magnesium stearate and mineral oil.Use the diluent or the adjuvant that often use, for example filler, supplement, binding agent, wetting agent, disintegrating agent and surfactant prepare said preparation.The solid preparation that is used for oral administration comprises tablet, pill, powder, granule, capsule or the like.Through mixing said extracted thing and at least a adjuvant, for example starch, calcium carbonate, sucrose or lactose, gelatin etc. prepare such solid preparations.In addition, except simple adjuvant, also make with lubricator, for example magnesium stearate and Pulvis Talci.The liquid preparation that is used for oral administration comprises suspending agent, liquid contents, emulsion, syrup etc.Except water and liquid paraffin, they are simple diluent of often using, can comprise several kinds of adjuvants, for example wetting agent, sweeting agent, odorant agent, antiseptic etc.The preparation that is used for non-oral administration comprises aqueous antiseptic solution, nonaqueous solvent, suspending agent, emulsion, lyophilized preparation and suppository.Can use vegetable oil, for example propylene glycol, Polyethylene Glycol and olive oil or injectable ester, for example ethyl oleate is as nonaqueous solvent or suspending agent.Can use sodium alginate (witepsol), Polyethylene Glycol (macrogol), tween 61, cocoa butter, bright mesophyll real (laurinum), glycerin gelatine as the suppository basis.
Absorption of active ingredient depends on the experimenter's that will treat age, sex and body weight, the judgement of some disease that will treat or seriousness, route of administration and the prescription of pathological state, disease or pathological state.Measure consumption in those skilled in the art's the level based on these parameters.Said consumption usually in 0.001mg/kg/ days to about 2000mg/kg/ days scope, more preferably 1mg/kg/ days to 100mg/kg/ days.Can once a day or divide and carry out administration several times.Never in any form within the scope of the present invention with the consumption restriction.
With respect to the gross weight of compositions, be used to prevent or the pharmaceutical composition of treatment and hepatocarcinoma diseases associated comprises 0.1 to 50 weight % crow conopsea extraction according to of the present invention.
Can extract of the present invention be administered to mammal through several kinds of approach, for example Mus, cattle and the mankind.Can predict all route of administration.For example, can administered through oral, rectum, intravenous injection or intramuscular injection, subcutaneous injection, in utero cerebral dura mater injection or cerebrovascular drug administration by injection.Extract of the present invention does not have toxicity basically and has no side effect, therefore to being used to prevent the sure medicine that uses of long term administration of purpose.
The present invention also provides a kind of health functional food, and it improves treatment for cancer with the acceptable food diet supplemented by additives that conforms with science, and it comprises crow ginseng and crow ginseng root hair.Health functional food of the present invention comprises the for example form of tablet, capsule, pill or liquid.Use can be added food in the The compounds of this invention to, for example several foods, beverage, chewing gum, Folium Camelliae sinensis, compound vitamin, health functional food or the like.
The invention effect
Identified with the crow ginseng of common technology preparation and compared that the crow ginseng of the present invention's preparation comprises the ginsenoside Rg who significantly increases
3Also identified increase ginsenoside Rg along with the steaming and decocting number of times
3Increase gradually.According to temperature and drying condition, the production of these things is responsive.
Steaming and decocting step through repeatedly under temperature of the present invention and conditions of cooking reduces the content of the benzopyrene that is known as carcinogen; It is removed to is lower than the safety criterion level; Can confirm in initial step of the present invention; Detect benzopyrene and surpass 1.0ppb, it is higher than standard level, but benzopyrene content is reduced to and is lower than standard level.Think and in the raw material Radix Ginseng, produce benzopyrene in the remaining pesticide.Thereby, go out the benzopyrene that produces through steaming and decocting repeatedly of the present invention and drying condition.In fact, detect the benzopyrene in the Radix Ginseng even before steaming and decocting.Have only and detect benzopyrene when using above-mentioned Radix Ginseng preparation crow to join.From beginning not detect benzopyrene, in the process of preparation crow ginseng, do not detect benzopyrene yet.
In addition, verified, compare with Radix Ginseng Rubra, have the ginsenoside Rg of increase
3Crow ginseng antagonism hepatocarcinoma have excellent anticancer effect.Just because of this, researched and developed the method for the crow ginseng that can prepare effective treatment hepatocarcinoma relevant disease and carcinogen safety.
Description of drawings
Fig. 1 shows the flow chart for preparing the method for crow ginseng according to the method for preferred embodiment 1.
Fig. 2 is the figure about the mtt assay testing result of the survivaling cell of HCC HepG2 that shows according to experimental embodiment 2-1.
The specific embodiment
Describe the preferred embodiment of the invention below in detail.Yet the present invention is not limited to embodiment described herein, can show other form.The embodiment that provides this paper to introduce is so that can thoroughly understand description and can exchange technical concept of the present invention with those skilled in the art completely.
Embodiment 1 <use identical condition: boiling temperature is 85 ℃, and baking temperature is 50 ℃, and total steaming and decocting number of times is 13, preparation crow ginseng main body and root hair, and preparation extract >
Collect the Radix Ginseng in 6 years, remove soil and foreign body.Clean this Radix Ginseng with pure water then, and remove moisture.Above-mentioned green ginseng is separated into main body and root hair (root).Each air drying 10kg of the main body of isolating Radix Ginseng and root hair, so that their moisture is not more than 14%, thus the preparation Radix Ginseng.With exsiccant Radix Ginseng be divided into Radix Ginseng main body and Radix Ginseng must, steaming and decocting is 10 hours under 85 ℃ temperature, under 50 ℃ temperature dry 4 hours then.Steaming and decocting and dry same repeat 12 times (13 steaming and decoctings altogether).When repeating steaming and decocting with drying, exsiccant Radix Ginseng becomes Radix Ginseng Rubra and Radix Ginseng Rubra becomes the crow ginseng.Through doing the main body and the root hair of preparation crow ginseng like this.Continue last drying and be not more than 10% until moisture.After this, main body and the extract of root hair, the main body and the root hair of grinding crow ginseng respectively in order to prepare the crow ginseng.Under 80 ℃ temperature, the main body and the root hair of the crow of grinding ginseng are placed on respectively in the 100L pure water, under the rotating speed of 60rpm, stir 8 hours, precipitate 3 hours then.The extract of filtering-depositing is to remove solid.Lyophilization filtrating and the blackest main body and root hair of joining are prepared into powder.
2-1. 80 ℃ of boiling temperatures
Except boiling temperature is 80 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-2. 90 ℃ of boiling temperatures
Except boiling temperature is 90 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Embodiment 3 < steaming and decocting number of times >
3-1. steaming and decocting six times (repeating steaming and decocting and drying 5 times)
Except total steaming and decocting number of times is six times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-2. steaming and decocting seven times (repeating steaming and decocting and drying 6 times)
Except total steaming and decocting number of times is seven times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-3. steaming and decocting eight times (repeating steaming and decocting and drying 7 times)
Except total steaming and decocting number of times is eight times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-4. steaming and decocting nine times (repeating steaming and decocting and drying 8 times)
Except total steaming and decocting number of times is nine times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-5. steaming and decocting ten times (repeating steaming and decocting and drying 9 times)
Except total steaming and decocting number of times is ten times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-6. steaming and decocting ten once (repeats steaming and decocting and drying 10 times)
Except total steaming and decocting number of times be ten once, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-7. steaming and decocting ten secondaries (repeating steaming and decocting and drying 11 times)
Except total steaming and decocting number of times is ten secondaries, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Except baking temperature is 25 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Comparative example 1 <boiling temperature >
1-1. 70 ℃ of boiling temperatures
Except boiling temperature is 70 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
1-2. 75 ℃ of boiling temperatures
Except boiling temperature is 75 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
1-3. 95 ℃ of boiling temperatures
Except boiling temperature is 95 ℃, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Comparative example 2 < total steaming and decocting number of times >
2-1. steaming and decocting once (repeats steaming and decocting and does not have drying)
Except total steaming and decocting number of times be once, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-2. twice of steaming and decocting (repeating steaming and decocting and drying once)
Except total steaming and decocting number of times is twice, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-3. steaming and decocting three times (repeating twice of steaming and decocting and drying)
Except total steaming and decocting number of times is three times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-4. steaming and decocting four times (repeating steaming and decocting and drying three times)
Except total steaming and decocting number of times is four times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-5. steaming and decocting five times (repeating steaming and decocting and drying four times)
Except total steaming and decocting number of times is five times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
2-6. steaming and decocting 14 times (repeating steaming and decocting and drying 13 times)
Except total steaming and decocting number of times is 14 times, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Comparative example 3 <baking temperature >
3-1.20℃
Except under 20 ℃, carrying out the drying, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
3-2.55℃
Except under 55 ℃, carrying out the drying, the main body of preparation crow ginseng and the extract of root hair under the condition identical with embodiment 1.
Comparative example 4 < preparation Radix Ginseng Rubra and Radix Ginseng Rubra root hair >
Be purchased and obtain Radix Ginseng Rubra root (Radix Ginseng Rubra main body) and the Radix Ginseng Rubra root hair in 6 years, and use pure water to prepare Radix Ginseng Rubra root and Radix Ginseng Rubra extract down with embodiment 1 identical mode at 80 ℃.
Experimental embodiment 1 < component analysis of crow ginseng >
Black conopsea extraction for preparing about the method through embodiment 1-4 and comparative example 1-3 and comparative example 4 Radix Ginseng Rubra extract have been analyzed its ginsenoside's composition.Known Radix Ginseng saponin constituent more is included in the rootlet.Therefore, in this experiment, use crow ginseng root hair and Radix Ginseng Rubra root hair respectively.
In the analysis of ginsenoside's composition, according to codex Alimentarius [the 4th joint. the red composition characterization test of method of testing (1) of the concentrated Radix Ginseng Rubra of food standard and requirement → 16. Radix Ginseng product → 16-10., high-speed liquid chromatography] carry out ginsenoside's detection method.
The numerical value of the content of ginsenoside of table 1 display analysis crow ginseng and Radix Ginseng Rubra.The result of table 1 confirms along with the steaming and decocting number of times increases, the ginsenoside R of crow ginseng
3Obviously increase; Especially, under eight steaming and decoctings, ginsenoside R
3Roll up; Under greater than nine steaming and decoctings, ginsenoside R
3Content remain on almost similar level.Confirm that also 80 to 89 ℃ near under 85 ℃ the temperature, ginsenoside R
G3And R
H1What increase is maximum.If confirm under too low temperature (20 ℃), to carry out drying, prepare complete inferior crow ginseng.Otherwise, ginsenoside R
G3And R
H1Content show low-level significantly.
Only for reference, the total thick saponin amount of the crow of validating analysis embodiment 1 ginseng is 508.9mg/g; In initial steaming and decocting, the thick saponin level of above-mentioned thick saponin is similar with comparative example 4 Radix Ginseng Rubra, increases but it increases along with the steaming and decocting number of times (not showing in the table).
Table 1
The analysis result of crow ginseng
2-1. the experiment of external anticancer effect (cell experiment)
In order to confirm the anticancer effect of crow ginseng, use the black conopsea extraction powder of embodiment 1 and comparative example 4 Radix Ginseng Rubra extract powder to be determined at the cell of surviving among the cancerous cell HepG2 alive.As crow ginseng, representational use Rg
3The extract of the embodiment 1 that content is high is to use crow ginseng root hair and Radix Ginseng Rubra root hair with experimental embodiment 1 identical mode.
At first, at 37 ℃, 5% CO
2Use 100 μ L cell culture mediums (DMEM comprises the 100U/mL penicillin, 100g/mL streptomycin and 10% Ox blood serum) to cultivate the 1 * 105/mL cell in 96 orifice plates in the incubator.At maximum concentration is under the 1000 μ g/mL, treats to 2 μ g/mL with the black conopsea extraction and the Radix Ginseng Rubra extract of experiment material, and cultivates 24 hours.Each hole is placed 200 μ L fresh medium and MTT (tetrazolium bromide, SIGMA company) is prepared into 2 μ g/mL concentration, adds 50 μ L, reacts 3 to 4 hours.Remove 220 μ L test materials in each hole; Only remaining 30 μ L purple materials, and to wherein adding 150 μ L dimethyl sulfoxide (DMSO), mixed well 10 minutes; The dissolution precipitation thing is measured OD (optical density) through absorption 540nm on the ELISA plate reader then.All results calculate the correction value of the absorption of measuring in the hole that does not have cultured cell relatively.Table 2 shows the result through the survivaling cell that occurs with black conopsea extraction treatment HCC.Fig. 2 is the figure that shows identical result.
Confirm under the concentration that is not more than 8 μ g/mL from the result of table 2 and Fig. 2; The black conopsea extraction of the embodiment of the invention 1 shows 50% inhibition activity to hepatoma cell proliferation; And this is for comparative example 3 Radix Ginseng Rubra extract, is the high concentration greater than 1000 μ g/mL to the inhibition activity of hepatoma cell proliferation 50%.Therefore, the crow ginseng of method of the present invention preparation has selectivity and to the excellent anticancer effect of HCC.
Table 2
The analysis of anticancer effect
2-2. the experiment of vivo antitumor effect (zoopery)
Comprise the 100U/mL penicillin in use, the HepG2 cell of place implanting in the Tissue Culture Flask of the DMEM of 100g/mL streptomycin and 10% Ox blood serum (Gibco BLR) cell culture medium, and in 95%CO2,37 ℃ incubator, cultivate.When adherent cell, with HBSS (Hanks balanced salt solution, Gibco BLR) clean it twice, collect 0.2% trypsin.Use nine six all BALB/c bases not have the hair mouse in every group of experiment as laboratory animal.Every kind of extract of unit oral administration with 300mg/kg every day.In the contrast, an administration pure water.At first, 1 * 107 HepG2 injection cell is advanced these and do not have in hair mouse tumor line with subculture after obtaining.Carry out three pill for tumor of subculture with acquisition recovery initial performance.Implantation tumour ball in eight groups of subculture.Tumor taking place concentrate before the necrosis, supplies the animal of the quick growth of enough blood and sacrificed.Rapid splitted outline portion is cut into specific dimensions, and (3 * 3mm) to process tumor fragment.This tumor fragment is placed on the end of the trocar and it is set, so that the end can reach the rear section of the left anterior fascicle of animal.The trocar is 360 ° of fast rotational and removing lightly.Therefore, the tumor sheet is set is placed on the desired location, and the sterilization cut-out.With initial dosing interval after 24 hours, this tests completion, carries out obduction with independent separating solids cancer, and measures weight.Use digital plethysmometer (plethysmometer) to measure actual volume, the result is presented in the table 3.
Table 3
2-1. vivo antitumor effect experiment (zoopery)
| Condition | Tumor weight (g) | Gross tumor volume (mm 2) |
| Contrast | 0.925±0.136 | 0.843±0.186 |
| The black conopsea extraction of embodiment 1 | 0.305±0.239 | 0.315±0.256 |
| Comparative example 4 Radix Ginseng Rubra extract | 0.726±0.215 | 0.636±0.233 |
The result of table 3 confirms to compare with Radix Ginseng Rubra extract, even in the liver cancer animal model experiment, the weight and volume of the inhibition tumor that black conopsea extraction of the present invention can be good.
Experimental embodiment 3 < check and analysis benzopyrene >
In this experiment, to use the root hair extract of crow ginseng and Radix Ginseng Rubra with experimental embodiment 1 and 2 identical modes.Carry out the benzopyrene analysis according to korean foods and FAD in " the benzopyrene experimental technique detailed rules and regulations of health functional food (i.e. crow ginseng) " of December in 2007 issue on the 31st.Crow ginseng main body (not being extract) with dichloromethane extraction 4g embodiment 1 to 4 and comparative example's 1 to 3 preparation concentrates, and is dissolved in normal hexane, and through the florisil box, drying is dissolved in acetonitrile and analyzes with high performance liquid chromatograph.The internal standard material uses 3-methyl ossein, and detector uses fluorescence detector.Post also uses anti-phase divisional type (C18 Supelco LC-PAH 4.6mm * 250mm I.D.), and analysis condition is presented in the following table 4.Replicate analysis five times, the result is presented in the following table 5.Benzopyrene confirms that " being not more than 1.0ppb " is " being lower than the safety criterion level ".
Table 4
The analysis result of benzopyrene
| Operation | Condition |
| Volume injected | 10μL |
| Column temperature | 35℃ |
| Mobile phase | Acetonitrile: H 2O＝8∶2 |
| The detector wavelength | Excite 295nm, measure wavelength 404nm |
| Flow rate | 1.0ml/min |
Table 5
The analysis result of the benzopyrene of the repeated measure that detects according to benzopyrene
The result of table 5 can confirm that in the initial conditions of cooking of preparation the present invention crow ginseng, the amount of benzopyrene is high, but along with the steaming and decocting number of times increases, the benzopyrene detection limit reduces gradually.Because when the benzopyrene amount is not more than above-mentioned 1.0ppb, it is safe adjusting it, so safety product can confirm the crow ginseng of embodiment 1 to 4 preparation the time.In addition, if the temperature of dry crow ginseng is higher than condition of the present invention, the benzopyrene amount not exclusively is reduced to and is lower than 1.0ppb so.Therefore, can confirm,, certainly remove the benzopyrene that can produce in the preparation crow ginseng according to granting of the present invention.
Only for reference, even before steaming and decocting, detect the benzopyrene in the Radix Ginseng.Opposite with expectation, the amount that detects benzopyrene is 1.02ppb.Therefore, do not detect the clean Radix Ginseng of benzopyrene before independent classification and the steaming and decocting steaming and decocting.Use the Radix Ginseng that does not detect benzopyrene in the crow ginseng of steaming and decocting,, do not detect benzopyrene (not being presented in the table) with previous opposite.
Crow ginseng produced according to the invention is added in medicine or the food, use as prevention and the positive medicament preparation of treatment peace then.As concrete especially embodiment, the present invention provides a kind of method of using crow ginseng main body and root hair preparation to comprise the medicine and the functional food of black conopsea extraction.
< application 1: the preparation embodiment of medicine >
1-1. preparation powder
The crow ginseng root hair extract powder of embodiment 1 ... ... ... ... ... ... 300mg
Lactose ... ... ... ... ... ... ... ... ... ... ..100mg
Pulvis Talci ... ... ... ... ... ... ... ... ... ... 10mg
The mixing mentioned component is also filled in airtight cloth with the preparation powder.
1-2. preparation tablet
The crow ginseng root hair extract powder of embodiment 1 ... ... ... ... ... ... 300mg
Corn starch ... ... ... ... ... ... ... ... ... .100mg
Lactose ... ... ... ... ... ... ... ... ... ... ..100mg
Magnesium stearate ... ... ... ... ... ... ... ... ... .2mg
Mix mentioned component, carry out film-making with the preparation tablet according to the method for preparing of convas tablet then.
1-3. preparation capsule
The crow ginseng root hair extract powder of embodiment 1 ... ... ... ... ... ... 300mg
Corn starch ... ... ... ... ... ... ... ... ... .100mg
Lactose ... ... ... ... ... ... ... ... ... ... ..100mg
Magnesium stearate ... ... ... ... ... ... ... ... ... .2mg
According to capsular method for preparing commonly used, mix mentioned component, in gelatine capsule, fill with the preparation capsule then.
< application 2: the preparation embodiment of health food >
2-1. preparation health food
The crow ginseng root hair extract powder of embodiment 1 ... ... ... ... ... ... 300mg
Vitamin mixtures ... ... ... ... ... ... ... ... ... balance
Vitamin A acetic acid ... ... ... ... ... ... ... ... ... .70 μ g
Vitamin E ... ... ... ... ... ... ... ... ... ... ..1.0mg
Vitamin B1 ... ... ... ... ... ... ... ... ... ... .0.13mg
Vitamin C ... ... ... ... ... ... ... ... ... ... ..10mg
Biotin ... ... ... ... ... ... ... ... ... ... 10 μ g
Nicotiamide ... ... ... ... ... ... ... ... ... ... 1.7mg
Folic acid ... ... ... ... ... ... ... ... ... ... ..50 μ g
Calcium pantothenate ... ... ... ... ... ... ... ... ... ... 0.5mg
Iron sulfate ... ... ... ... ... ... ... ... ... ... 1.75mg
Zinc oxide ... ... ... ... ... ... ... ... ... ... 0.82mg
Magnesium carbonate ... ... ... ... ... ... ... ... ... ... 25.3mg
Single potassium phosphate ... ... ... ... ... ... ... ... ... ... .15mg
Calcium hydrogen phosphate ... ... ... ... ... ... ... ... ... ... .55mg
Potassium citrate ... ... ... ... ... ... ... ... ... ... .90mg
Calcium carbonate ... ... ... ... ... ... ... ... ... ... 100mg
Magnesium chloride ... ... ... ... ... ... ... ... ... ... 24.8mg
The compositions that the one-tenth assignment system that is suitable for health food such as preferential preparation embodiment is comprised the mixture of said vitamin and mineral through mixed phase.Can change their mixed proportion arbitrarily.Mix said mixture with the preparation granule according to the method for preparation health food commonly used.Can use this granule preparing in the health-care food composition according to common method.
2-2. preparation health beverage
The crow ginseng root hair extract powder of embodiment 1 ... ... ... ... ... ... ... 500mg
Citric acid ... ... ... ... ... ... ... ... ... ... 100mg
Oligosaccharide ... ... ... ... ... ... ... ... ... ... 100g
Flos Mume extract ... ... ... ... ... ... ... ... ... ..2g
Taurine ... ... ... ... ... ... ... ... ... ... 1g
The pure water that adds ... ... ... ... ... ... ... ... ... 900mL
Method according to preparation health beverage commonly used is mixed mentioned component, heats about 1 hour down at 85 ℃.The solution that produces is like this filtered and is placed in the disinfecting container (2L), and sterilization and cold preservation are to prepare health beverage compositions of the present invention.
Beverage that is suitable for missing potter relatively through mixing such as the one-tenth assignment system above-mentioned composition of preferred preparation embodiment.Yet, can for example demand, demand be regional, purposes with national taste according to the area, change their mixed proportion arbitrarily.
Claims (5)
1. a method for preparing black conopsea extraction, wherein ginsenoside R
G3Content is not more than 1.0ppb greater than the detection limit of 130mg and benzopyrene, and it comprises:
First process is cleaned Radix Ginseng and it is separated into the step of Radix Ginseng main body and Radix Ginseng palpus;
Second process, dry Radix Ginseng main body and the Radix Ginseng that cleans must make their moisture be no more than 14% step;
The 3rd process, the Radix Ginseng main body of difference boiling and drying and 8～10 hours step of Radix Ginseng palpus under 80～90 ℃ temperature;
The 4th process, the Radix Ginseng main body of difference drying and cooking and 3～5 hours step of Radix Ginseng palpus under 25～50 ℃ temperature;
The five faults in diagnosis and treatment journey, the steaming and decocting in continuous 5～12 repetition the 3rd processes and 25～50 ℃ of exsiccant steps in the 4th process; With
The 6th process, dry repetition steaming and decocting and dry crow ginseng main body and the root hair that obtains from the five faults in diagnosis and treatment journey make their moisture finally be no more than 10% step under 25～50 ℃ temperature.
The 7th process, with the crow of solvent extraction the 6th step ginseng, from extract, remove solvent and dry it to prepare the step of black conopsea extraction.
2. according to the method for preparing the crow ginseng of claim 1, wherein the Radix Ginseng of first process is the Radix Ginseng in 4 to 6 years.
3. according to the method for preparing the crow ginseng of claim 1, wherein be herbaceos perennial, belong to the Panax, and comprise Radix Ginseng, Radix Panacis Quinquefolii, Radix Notoginseng, Panax vietnamensis Ha et Grushv., Panax pseudo-ginseng Wall. var. elegantior (Burkill)Hoo & Tseng, narrow leaf Rhizoma Panacis Japonici or Rhizoma Panacis bipinnatifidi.
4. be used to prevent or improve the health food of hepatocarcinoma, it comprises the crow ginseng as the claim 1 of effective ingredient.
5. be used to prevent or treat the pharmaceutical composition of hepatocarcinoma, it comprises the crow ginseng as the claim 1 of effective ingredient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2009-0095003 | 2009-10-07 | ||
| KR1020090095003A KR100972941B1 (en) | 2009-10-07 | 2009-10-07 | Composition comprising an extract of black ginseng for preventing or treating hepatoma |
| PCT/KR2010/006744 WO2011043564A2 (en) | 2009-10-07 | 2010-10-04 | Composition containing black ginseng extracts for preventing or treating liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102711779A true CN102711779A (en) | 2012-10-03 |
Family
ID=42646131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800554591A Pending CN102711779A (en) | 2009-10-07 | 2010-10-04 | Composition containing black ginseng extracts for preventing or treating liver cancer |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100972941B1 (en) |
| CN (1) | CN102711779A (en) |
| WO (1) | WO2011043564A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873558A (en) * | 2015-06-11 | 2015-09-02 | 北京凯宾鸿生物医药科技有限公司 | Preparation method of black ginseng with high-content ginsenoside |
| CN107737146A (en) * | 2017-11-21 | 2018-02-27 | 扬州大学 | Panax japonicus piece and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101369638B1 (en) | 2012-01-04 | 2014-03-06 | 주식회사 한국인삼공사 | Methods for Preparing Red Ginseng with Prevented Body Crack |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600795B1 (en) * | 2006-01-18 | 2006-07-19 | (주) 흑삼코리아 | A black ginseng having excel content of ginsenoside rg3 ingredient and the concentrate of black ginseng |
| KR100729214B1 (en) * | 2006-11-07 | 2007-06-19 | (주)고려바이오홍삼 | Making manufacture of black ginseng |
| WO2007133054A1 (en) * | 2006-05-17 | 2007-11-22 | The Industry & Academic Cooperation In Chungnam National University (Iac) | A novel process for preparing black ginseng and the composition comprising the same |
| KR20080014464A (en) * | 2006-08-11 | 2008-02-14 | 박용진 | A composition comprising novel black ginseng leaf and the extract thereof showing anti-oxidative activity prepared by novel process |
| WO2008075866A1 (en) * | 2006-12-18 | 2008-06-26 | Yong Jin Park | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer |
| CN101278954A (en) * | 2007-04-04 | 2008-10-08 | 赵方林 | Ginseng or American ginseng product with increased content of ginseng saponin Rg3 and method of preparing the same |
| KR20090041214A (en) * | 2007-10-23 | 2009-04-28 | (주) 행복에프씨 | Making manufacture of black ginseng |
| KR20090093310A (en) * | 2008-02-29 | 2009-09-02 | 강신정 | Benzopyrene reduced red and black ginseng manufacturing method |
| KR20090095354A (en) * | 2008-03-05 | 2009-09-09 | 주식회사 엔유씨전자 | Black ginseng making apparatus and method for making black ginseng using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100529475B1 (en) * | 2002-11-15 | 2005-11-21 | 김항종 | Making method of black ginseng |
| KR100692294B1 (en) * | 2006-08-31 | 2007-03-12 | 박춘자 | Manufacturing method of black ginseng extracts having chemopreventive effect about large intestine cancer |
| KR101082181B1 (en) * | 2007-05-31 | 2011-11-09 | 박용진 | A method for preparing novel black-red ginseng and the extract therefrom and the composition comprising the same |
-
2009
- 2009-10-07 KR KR1020090095003A patent/KR100972941B1/en active IP Right Grant
-
2010
- 2010-10-04 WO PCT/KR2010/006744 patent/WO2011043564A2/en active Application Filing
- 2010-10-04 CN CN2010800554591A patent/CN102711779A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600795B1 (en) * | 2006-01-18 | 2006-07-19 | (주) 흑삼코리아 | A black ginseng having excel content of ginsenoside rg3 ingredient and the concentrate of black ginseng |
| WO2007133054A1 (en) * | 2006-05-17 | 2007-11-22 | The Industry & Academic Cooperation In Chungnam National University (Iac) | A novel process for preparing black ginseng and the composition comprising the same |
| KR20080014464A (en) * | 2006-08-11 | 2008-02-14 | 박용진 | A composition comprising novel black ginseng leaf and the extract thereof showing anti-oxidative activity prepared by novel process |
| KR100729214B1 (en) * | 2006-11-07 | 2007-06-19 | (주)고려바이오홍삼 | Making manufacture of black ginseng |
| WO2008075866A1 (en) * | 2006-12-18 | 2008-06-26 | Yong Jin Park | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer |
| CN101278954A (en) * | 2007-04-04 | 2008-10-08 | 赵方林 | Ginseng or American ginseng product with increased content of ginseng saponin Rg3 and method of preparing the same |
| KR20090041214A (en) * | 2007-10-23 | 2009-04-28 | (주) 행복에프씨 | Making manufacture of black ginseng |
| KR20090093310A (en) * | 2008-02-29 | 2009-09-02 | 강신정 | Benzopyrene reduced red and black ginseng manufacturing method |
| KR20090095354A (en) * | 2008-03-05 | 2009-09-09 | 주식회사 엔유씨전자 | Black ginseng making apparatus and method for making black ginseng using the same |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873558A (en) * | 2015-06-11 | 2015-09-02 | 北京凯宾鸿生物医药科技有限公司 | Preparation method of black ginseng with high-content ginsenoside |
| CN107737146A (en) * | 2017-11-21 | 2018-02-27 | 扬州大学 | Panax japonicus piece and preparation method thereof |
| CN107737146B (en) * | 2017-11-21 | 2021-04-02 | 扬州大学 | Panax japonicus slice and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011043564A3 (en) | 2011-09-01 |
| KR100972941B1 (en) | 2010-07-29 |
| WO2011043564A2 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103037882B (en) | Composition for preventing or treating osteoporosis, containing ssangwhatang or lactobacillus fermented product thereof | |
| CN101637492B (en) | Preparation method of total flavonoids in persimmon leaves | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| WO2007133054A1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
| KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
| KR20120109141A (en) | Composition for treatment of lung cancer and functional food comprising extract of gleditsiae semen | |
| JP4496127B2 (en) | Herbal extract mixture and preventive or therapeutic agent for osteoporosis | |
| WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
| JP2018521003A (en) | Composition for prevention or treatment of benign prostatic hyperplasia containing sykunshi extract | |
| CN102711779A (en) | Composition containing black ginseng extracts for preventing or treating liver cancer | |
| KR20150051845A (en) | Pharmaceutical composition and healthy food for alleviating climacteric syndrome | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN106310034A (en) | Pharmaceutical composition for increasing bone density and preparation method thereof | |
| CN108367038A (en) | The composition for preventing or treating climacteric obstacle containing New Zealand spinach extract | |
| KR20050100890A (en) | Composition comprising the extract of acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| CN109463758A (en) | A kind of anti-aging and the compound product and preparation method thereof for increasing moisture of skin | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN108157969A (en) | A kind of blood-enriching face-nourishing composition and preparation method thereof | |
| CN115737747B (en) | Traditional Chinese medicine composition for improving memory and preventing and treating senile dementia and application thereof | |
| CN107432889A (en) | Menopause symptom or osteoporosis improvement composition | |
| KR101209646B1 (en) | Pharmaceutical compositions containing the extracts of Araneus ventricosus for increasing immune cell number or inhibiting metastasis of cancer or proliferation of hepatitis virus | |
| KR20120109139A (en) | Composition for treatment of lung cancer and functional food comprising extract of melandrii herba | |
| KR20120109790A (en) | Composition for treatment of lung cancer and functional food comprising extract of olibanum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121003 |